Clomiphene citrate therapy for luteal phase defect.

Area of Science:

• Reproductive Endocrinology
• Infertility Research

Background:

• Luteal phase defect (LPD) is a recognized cause of infertility.
• Understanding LPD's impact on conception rates is crucial for effective treatment.

Purpose of the Study:

• To determine the conception rate in infertility patients with luteal phase defects undergoing clomiphene citrate therapy.
• To identify factors influencing treatment response and conception.

Main Methods:

• Life-table analysis was employed to assess conception rates.
• Patient subgroups based on response to clomiphene citrate therapy were identified.
• Endometrial biopsy delay was analyzed in relation to conception outcomes.

Main Results:

• The overall crude conception rate was 40.9%.
• Patients with LPD and no other infertility factors who conceived had a significantly longer mean biopsy delay (6.28 days) compared to those who did not (4.32 days).
• A histologic delay of 5 days or more was associated with a 79% conception rate, versus 8.9% for less severe delays.

Conclusions:

• Clomiphene citrate therapy demonstrates varied efficacy in patients with luteal phase defects.
• The severity of endometrial histologic delay is a significant predictor of conception success.
• Subgroup analysis reveals distinct responses to therapy, highlighting the importance of individualized treatment approaches.